Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors

Non-small cell lung cancer (NSCLC) patients carrying specific EGFR kinase activating mutations (L858R, delE746-A750) respond well to tyrosine kinase inhibitors (TKIs). However, drug resistance develops within a year. In about 50% of such patients, acquired drug resistance is attributed to the enrich...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Ray, Paramita, Tan, Yee Sun, Somnay, Vishal, Mehta, Ranjit, Sitto, Merna, Ahsan, Aarif, Nyati, Shyam, Naughton, John P., Bridges, Alexander, Zhao, Lili, Rehemtulla, Alnawaz, Lawrence, Theodore S., Ray, Dipankar, Nyati, Mukesh K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356576/
https://ncbi.nlm.nih.gov/pubmed/27612423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11860
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi